Publication:
Elite controllers and lessons learned for HIV-1 cure

dc.contributor.authorLopez-Galindez, Luis Cecilio
dc.contributor.authorPernas, Maria
dc.contributor.authorCasado, Concepcion
dc.contributor.authorOlivares, Isabel
dc.contributor.authorLorenzo-Redondo, Ramon
dc.contributor.funderMinisterio de Economía (España)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderRETICS-Sida (RIS-ISCIII) (España)
dc.date.accessioned2025-01-15T11:13:00Z
dc.date.available2025-01-15T11:13:00Z
dc.date.issued2019-10
dc.description.abstractFollowing the success of HIV-1 antiviral treatment that maintains undetectable levels of viral replication and lack of clinical progression, the design of an HIV-1 cure for patients became the next objective. The success of the treated individuals together with the identification of subjects that spontaneously control the clinical progression for long periods, such as long-term non-progressors (LTNPs) and particularly LTNP Elite Controllers (LTNP EC) have shed hope for the feasibility of a potential cure. Although a successful cure has not been attained yet, these patients have provided critical information on the mechanisms involved in the clinical control such as host genetic factors, as well as strong immune responses against the virus. Less attention has been paid to virological factors, particularly the association of the genetic variability and the control of viral infection. Considering all these studies, it has become clear that a combination of several host, immune and viral factors is needed to attain control of the viral replication control and the non-progressor clinical phenotype. Because this control can be reached through different combinations of factors, this group of individuals is not homogenous. As HIV-1 cure has been shown to be extremely difficult to achieve, a more feasible objective is the functional cure of the viral infection. After the analysis of multiple studies on the mechanisms of control in LTNP EC, we found subjects with various host protective factors and prolonged viral control. These subjects present a complete lack of evolution after more than 20-30 years of infection, stable levels of CD4+ cells (>400-500 cells/μl), a strong immune response, and no signs of clinical progression. We propose that individuals with these characteristics could have attained a functional cure of the HIV-1 infection.
dc.description.peerreviewed
dc.description.sponsorshipWork in the VM group in the ISCIII was supported by grants SAF (2010-17226) and (2016-77894-R) from MINECO (Spain) and FIS (PI 13/02269, ISCIII) and in part by the RIS-RETIC grants RD06/006/0036 and RD12/0017/0028 funded by the ISC III-FEDER. MP has a contract of RIS-RETIC RD12/0017/0036. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
dc.format.page31-36
dc.format.volume38
dc.identifier.citationLopez-Galindez C, Pernas M, Casado C, Olivares I, Lorenzo-Redondo R. Elite controllers and lessons learned for HIV-1 cure. Curr Opin Virol. 2019 Oct;38:31-36.
dc.identifier.doi10.1016/j.coviro.2019.05.010
dc.identifier.e-issn1879-6265
dc.identifier.issn1879-6257
dc.identifier.journalCurrent opinion in virology
dc.identifier.pubmedID31252326
dc.identifier.urihttps://hdl.handle.net/20.500.12105/26025
dc.language.isoeng
dc.publisherElsevier
dc.relation.projectIDinfo:eu-repo/grantAgreement/MICINN//SAF2010-17226/ES/CARACTERIZACION DE VARIANTES NO PATOGENICOS DEL VIH OBTENIDOS "EX VIVO" E "IN VITRO" PARA EL ESTUDIO DE LA PATOGENIA DE LA INFECCION/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2016-77894-R
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI13/02269
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD12/0017/0036
dc.relation.publisherversionhttps://doi.org/10.1016/j.coviro.2019.05.010
dc.repisalud.centroISCIII::Centro Nacional de Microbiología (CNM)
dc.repisalud.institucionISCIII
dc.rights.accessRightsopen access
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.meshAntiviral Agents
dc.subject.meshClinical Trials as Topic
dc.subject.meshDisease Progression
dc.subject.meshHIV Infections
dc.subject.meshHIV Long-Term Survivors
dc.subject.meshHIV-1
dc.subject.meshHumans
dc.subject.meshImmunologic Factors
dc.subject.meshTranscription, Genetic
dc.subject.meshViral Load
dc.subject.meshVirus Latency
dc.subject.meshVirus Replication
dc.titleElite controllers and lessons learned for HIV-1 cure
dc.typereview article
dc.type.hasVersionAM
dspace.entity.typePublication
relation.isAuthorOfPublicationf57c2687-907b-44ea-a780-7920ff8b9b41
relation.isAuthorOfPublicationcca7e901-0913-4b71-8c9d-ee7dd20b6458
relation.isAuthorOfPublication7e48a263-54c3-4de0-81e7-f7446c918f2d
relation.isAuthorOfPublication891fcdfd-85a1-46ac-944b-ac6de54d3cc9
relation.isAuthorOfPublication.latestForDiscoveryf57c2687-907b-44ea-a780-7920ff8b9b41
relation.isFunderOfPublicationca7182dc-aaab-45ec-a09d-755563fe05f2
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublicationcf779d8b-1517-4249-81b7-65344ce5172d
relation.isFunderOfPublication.latestForDiscoveryca7182dc-aaab-45ec-a09d-755563fe05f2
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files

Original bundle

Now showing 1 - 3 of 3
Loading...
Thumbnail Image
Name:
EliteControllersLessonsLearned_HIV-1_2019.pdf
Size:
933.88 KB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Figura1_EliteControllersLessonsLearned_HIV-1_2019.png
Size:
107.62 KB
Format:
Portable Network Graphics
Loading...
Thumbnail Image
Name:
Graphic_Summary_EliteControllersLessonsLearned_HIV-1_2019.png
Size:
171.91 KB
Format:
Portable Network Graphics